# Data Sharing Statement

| Item | Question                                                                 | Authors’ Response (place “-” if not applicable) |
|------|---------------------------------------------------------------------------|-----------------------------------------------|
| 1    | Would you like to share data collected for your study to others?          | Yes.                                          |
| 2    | If not, would you like to share the reason for your decision?             | -                                             |
| 3    | What data in particular will be shared?                                   | The Cell inhibition rate will be shared, and we also found a synergistic effect between Metformin and 5-ALA with OPDT. |
| 4    | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan and informed consent form will also be shared if requested. |
| 5    | When will data availability begin?                                        | From the publication date.                    |
| 6    | When will data availability end?                                          | Two years within the publication date, since the technique or survival date may be updated over time |
| 7    | To whom will you share the data?                                         | Medical oncologists and breast surgeons who are interested in this study. |
| 8    | For what type of analysis or purpose?                                     | For analysis to evaluate the OPDT in TNBC.     |
| 9    | How or where can the data/documents be obtained?                         | Emails could be sent to the address below to obtain the shared data: pei63052161@139.com |
| 10   | Any other restrictions?                                                   | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |